Share your videos with the world

The following statement is being issued by Branstetter, Stranch & Jennings, PLLC regarding In re Prograf Antitrust Litigation. A lawsuit is currently pending claiming that Astellas Pharma US, Inc. (“Astellas” or “Defendant”) violated state antitrust, unfair competition, consumer protection, and unjust enrichment laws of certain states by delaying the availability of a less expensive generic version of the immunosuppressant prescription drug Prograf® (known as tacrolimus). Plaintiffs allege that Defendant’s conduct caused some consumers and third party payors to pay too much for Prograf in certain states from September 3, 2008 to December 31, 2010 (also referred to as the “Class Damage Period”). This lawsuit does not claim that Prograf is unsafe or ineffective. Astellas denies any wrongdoing. To view the multimedia release go to: http://www.multivu.com/players/English/7933851-prograf-antitrust-class-action-settlement/